Tukavo 150mg Tablet Supplier USA | Pharmaceutical Exporter from India

Tukavo 150mg Tablet: Advanced HER2-Positive Breast Cancer Therapy  

Are you searching for a reliable Tukavo 150 mg tablet exporter from India? Ernest Oncology, a premier division of Ernest Pharmaceutical Pvt. Ltd., is a leading global supplier and bulk distributor of specialized targeted therapies. We provide a robust supply chain to the UK (London), USA, UAE (Abu Dhabi), Australia, and South Africa, ensuring that high-intensity oncology medications reach healthcare providers and specialized pharmacies with efficiency and regulatory precision.

Detailed Product Overview: What is Tukavo 150mg?

Tukavo 150 mg contains Tucatinib, a potent and highly selective oral tyrosine kinase inhibitor (TKI). It is specifically designed to target the HER2 (Human Epidermal Growth Factor Receptor 2) protein, which is overexpressed in certain types of breast cancer. Unlike many other HER2 inhibitors, Tukavo has shown a remarkable ability to cross the blood-brain barrier, making it a critical component in treating patients with brain metastases.

The 150mg tablet is the standard therapeutic dose, typically used in combination with other medications to significantly improve progression-free survival and overall survival in patients with advanced metastatic disease.

Primary Therapeutic Indications: 

Tukavo 150 mg is clinically indicated for:

• HER2-Positive Metastatic Breast Cancer: Used in combination with trastuzumab and capecitabine for adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including those with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.

• RAS Wild-Type HER2-Positive Colorectal Cancer: Recently gaining traction in combination with trastuzumab for patients with advanced colorectal cancer that has progressed after standard chemotherapy.

Mechanism of Action: How Tukavo 150 mg Works: 

Tukavo exerts its anti-cancer effects through a highly targeted biochemical pathway:

1. Selective HER2 Inhibition: Tukavo specifically inhibits the phosphorylation of HER2, which blocks the downstream signaling pathways (like PI3K/Akt and MAPK) that tell cancer cells to grow and divide.

2. Selectivity over EGFR: One of the key benefits of Tukavo is its high selectivity for HER2 over EGFR. This results in fewer "off-target" side effects, such as severe skin rashes or diarrhea, commonly seen with non-selective inhibitors.

3. CNS Penetration: Tukavo is uniquely effective at penetrating the Central Nervous System (CNS), allowing it to treat secondary tumors that have spread to the brain—a common complication in HER2-positive metastatic breast cancer.

Administration and Dosage: 

• Route: Oral administration (tablets).

• Standard Dosage: The recommended dose is 300 mg (two 150 mg tablets) taken orally twice daily.

• Combination Usage: It is almost always taken in a specific cycle alongside capecitabine (oral) and trastuzumab (IV or subcutaneous).

• Instructions: Tablets should be swallowed whole and can be taken with or without food.

Safety Profile & Monitoring:

Healthcare professionals monitor patients for the following:

• Hepatotoxicity: Regular liver function tests (ALT, AST, and bilirubin) are required before and during treatment.

• Diarrhea: While less severe than other TKIs, diarrhea is a common side effect and should be managed with anti-diarrheal medication at the first sign.

• Common Side Effects: Nausea, fatigue, vomiting, and palmar-plantar erythrodysesthesia (hand-foot syndrome) due to the combination with capecitabine.

Why Source Tukavo 150 mg from Ernest Oncology?

• Verified Supply Chain: Direct procurement from GMP-certified facilities, ensuring 100% authenticity for every exporter from India shipment.

• Global Logistics Mastery: Expertise in handling cold-chain requirements and international regulatory paperwork for the USA, UK, UAE, Australia, and South Africa. 

• Bulk Availability: Consistent stock levels to support large-scale hospital supplies and international pharmacy distributors.

• B2B Partnership Focus: Competitive wholesale pricing and real-time track-and-trace logistics.